BHVNBiohaven Ltd.

NYSE biohavenpharma.com


$ 38.87 $ 2.29 (6.25 %)    

Friday, 09-Aug-2024 15:59:56 EDT
QQQ $ 450.22 $ 2.34 (0.52 %)
DIA $ 395.16 $ 0.63 (0.16 %)
SPY $ 532.81 $ 2.34 (0.44 %)
TLT $ 96.28 $ 0.94 (0.99 %)
GLD $ 224.54 $ 0.55 (0.25 %)
$ 38.91
$ 38.87 x 100
-- x --
-- - --
$ 16.45 - $ 62.21
854,535
na
2.65B
$ 1.84
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-09-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 02-29-2024 12-31-2023 10-K
4 11-14-2023 09-30-2023 10-Q
5 07-31-2023 06-30-2023 10-Q
6 05-12-2023 03-31-2023 10-Q
7 03-23-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 biohaven-q2-adj-350-misses-177-estimate

Biohaven (NYSE:BHVN) reported quarterly losses of $(3.50) per share which missed the analyst consensus estimate of $(1.77) by 9...

 morgan-stanley-initiates-coverage-on-biohaven-with-overweight-rating-announces-price-target-of-58

Morgan Stanley analyst Terence Flynn initiates coverage on Biohaven (NYSE:BHVN) with a Overweight rating and announces Price...

 rbc-capital-reiterates-outperform-on-biohaven-maintains-59-price-target

RBC Capital analyst Leonid Timashev reiterates Biohaven (NYSE:BHVN) with a Outperform and maintains $59 price target.

 hc-wainwright--co-reiterates-buy-on-biohaven-maintains-59-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Biohaven (NYSE:BHVN) with a Buy and maintains $59 price target.

 cantor-fitzgerald-reiterates-overweight-on-biohaven

Cantor Fitzgerald analyst Charles Duncan reiterates Biohaven (NYSE:BHVN) with a Overweight.

 biohaven-stock-stumbles-as-protein-degrading-drug-falls-short-of-expectations-in-early-stage-study

Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations.

 whats-going-on-with-biohaven-stock-wednesday

The company announced it dosed a patient with a new possible treatment for certain cancers, showcased positive data from two di...

 biohaven-highlights-development-and-regulatory-advances-across-therapeutic-areas-and-progress-of-degrader-pipeline-at-2024-investor-rd-day

Reports new interim data from the ongoing Phase 1 study of BHV-1300, Biohaven's lead investigational drug from its Molecula...

 this-biotech-stock-is-poised-for-80-upside-with-breakthrough-in-obesity-drug-market-says-jpmorgan

The Structure Therapeutics stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the s...

 hc-wainwright--co-maintains-buy-on-biohaven-lowers-price-target-to-59

HC Wainwright & Co. analyst Douglas Tsao maintains Biohaven (NYSE:BHVN) with a Buy and lowers the price target from $63 ...

 ubs-maintains-buy-on-biohaven-raises-price-target-to-60

UBS analyst Ashwani Verma maintains Biohaven (NYSE:BHVN) with a Buy and raises the price target from $59 to $60.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION